

## Anti-human Endoglin/CD105 (clone MAEND 3)

Catalog No: MP-AA-9

---

### BACKGROUND

Endoglin/CD105, a homodimeric, transmembrane glycoprotein composed of disulphide-linked subunits of 95 kDa. It is the most reliable marker of proliferation of endothelial cells. It is over expressed on tumor neo-vasculature.

The available information indicates Endoglin as a powerful diagnostic and therapeutic target in human malignancies, through the imaging and the inhibition of tumor related angiogenesis.

### PRODUCT

1. Each vial contains the indicated amount of IgG (caprylic acid purified) in 0,1% gelatine and 0,05% NaN<sub>3</sub>.
2. Unpurified reagent is provided at the indicated amounts with 0.1% NaN<sub>3</sub>.  
Centrifuge the vial prior to use.

### SPECIFICITY

Mab MAEND3 (IgG1) recognizes native CD105.

### STORAGE

Store frozen and avoid repeated freeze-thawing.  
Stable for 2 yrs.

### SHIPPING CONDITIONS

Room temperature.

### RESEARCH USE

This antibody is for laboratory research use only, not for human or in-vivo use.

### APPLICATIONS

#### *Flow cytometry*

10-20 µg/ml on human umbilical vein endothelial cells (HUVEC) (ref. 1,2,3).

#### *Immunohistochemistry (fluorescence, enzymatic)*

Acetone-fixed cryostat sections (10-20 µg/ml).

#### *Immunoprecipitation*

5 µg, using rabbit anti-murine Ig and protein A-Sepharose beads (ref.1).

#### *Dot Blot Assay for soluble Endoglin*

Mab MAEND3 (5 µg/ml) recognizes soluble endoglin in conditioned medium from HUVEC, various cancer cell lines, and in sera of patients with melanoma and myeloid malignancies (ref. 3,4).

### REFERENCES

1. *J Cancer* (1996) **74**: 1586-1591.
  2. *Clin Cancer Res* (2000) **6**: 2037-2043.
  3. *J Cell Physiol* (2001) **188**: 1-7.
  4. *J Cell Physiol* (2002) **194**: 17.
-